Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, J. K. Altman, Richard M. Stone, Daniel J. Deangelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Christophe Willekens, Paresh VyasAlessandra Tosolini, Qiang Xu, Robert D. Knight, Katharine E. Yen, Sam Agresta, Stephane De Botton, Martin S. Tallman

Research output: Contribution to journal › Article › peer-review

1080 Scopus citations

Fingerprint

Dive into the research topics of 'Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds